HC Wainwright raised its 2027 earnings per share (EPS) estimate for Zevra Therapeutics from $0.46 to $0.55 on August 10. The firm maintained its Buy rating and a $26.00 price target for the stock.
Zevra reported second-quarter financial results on August 5. The company posted a quarterly EPS of $0.25. This result more than doubled the consensus estimate of $0.11. Quarterly revenue also exceeded analyst expectations.
Other analysts issued bullish revisions following the report. Citizens JMP increased its price target for Zevra from $25.00 to $28.00.